Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Artiva Biotherapeutics (Nasdaq: ARTV) said its management will participate in a panel and a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 2:15 p.m. EDT.
Audio webcast and archived recording will be available via the company's Investors page and remain available for replay for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – ARTV
In the Apr 8 session, ARTV declined 7.20%, reflecting a notable negative market reaction. Argus tracked a peak move of +11.4% during that session. Argus tracked a trough of -5.2% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Full-year 2025 earnings | Positive | +17.3% | Reported 2025 results, AlloNK progress, and cash runway into Q2 2027. |
| Feb 25 | Conference participation | Neutral | +0.2% | Announced fireside chat at TD Cowen health care conference with 90-day webcast. |
| Feb 24 | CFO appointment | Positive | +4.6% | Named new CFO with 30+ years’ experience and granted 220,000 RSUs. |
| Feb 19 | Board appointment | Positive | +9.2% | Added experienced biopharma executive Elaine Sorg to the board. |
| Jan 21 | Scientific meeting presentations | Positive | +2.8% | Planned Tandem Meetings posters on AlloNK cost-effectiveness and lymphoma durability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news (earnings, management changes, conferences) has generally been followed by positive price reactions for ARTV.
Over the last several months, ARTV’s news flow has centered on financing runway, AlloNK clinical progress, and visibility-building events. Full-year 2025 results on Mar 10, 2026 with $108.0M cash and advancing trials saw a 17.27% gain. Management upgrades in February (new CFO and director) produced single‑ to high‑single‑digit increases. Conference and scientific meeting participation in February and January also saw modest positive moves. Against this backdrop, today’s conference-participation headline resembles prior visibility events, though the pre-news setup shows shares already well above the 200-day MA.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a panel as well as a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 2:15 p.m. EDT.
To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com
Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
